Relationship between Drug Metabolism and Intestinal Microbiota in Parkinson's Disease Masaaki Hirayama 1 , Kinji Ohno 2 , Masahisa Katsuno 3 1Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine 2Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicin 3Department of Neurology, Nagoya University Graduate School of Medicine Keyword: パーキンソン病 , 腸内細菌 , L-ドパ , Enterococcus faecalis , 短鎖脂肪酸 , Parkinson's disease , intestinal microbiota , L-dopa , short chain fatty acid pp.805-809
Published Date 2020/7/1
DOI https://doi.org/10.11477/mf.1416201599
  • Abstract
  • Look Inside
  • Reference


The incidence of Parkinson's disease (PD) increases with age. PD is a neurodegenerative disease with an incidence of 1 in 200 individuals aged over 65 years. In patients with PD, α-synuclein may accumulate abnormally and damage cells in the substantia nigra. Abnormal proteins (α-synuclein) in peripheral tissues were recently found to be transferred to the brain rather than originating in the brain. Furthermore, changes in intestinal microbiota appear to be related to observed treatment effects and disease development in patients with PD. This review will report on recent studies of intestinal microbiota potentially involved in PD symptoms and progression.

Copyright © 2020, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院